Apogee Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APGE research report →
Companywww.apogeetherapeutics.com
Apogee Therapeutics, Inc. , through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
- CEO
- Michael Thomas Henderson
- IPO
- 2023
- Employees
- 196
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $5.03B
- P/E
- -20.65
- P/S
- 0.00
- P/B
- 4.52
- EV/EBITDA
- -15.44
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -32.64%
- ROIC
- -24.15%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-255,843,000 · -40.46%
- EPS
- $-4.22 · -27.88%
- Op Income
- $-285,595,000
- FCF YoY
- -34.97%
Performance & Tape
- 52W High
- $95.31
- 52W Low
- $34.34
- 50D MA
- $81.61
- 200D MA
- $64.43
- Beta
- 0.69
- Avg Volume
- 886.77K
Get TickerSpark's AI analysis on APGE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | HENDERSON MICHAEL THOMAS | sell | 18,659 |
| May 13, 26 | HENDERSON MICHAEL THOMAS | sell | 1,341 |
| May 6, 26 | Dambkowski Carl | other | 4,125 |
| May 6, 26 | Dambkowski Carl | sell | 3,700 |
| May 6, 26 | Dambkowski Carl | sell | 1,800 |
| May 6, 26 | Dambkowski Carl | other | 4,125 |
| May 1, 26 | Henderson Jane | sell | 811 |
| May 1, 26 | Henderson Jane | sell | 900 |
| May 1, 26 | Henderson Jane | sell | 289 |
| Apr 16, 26 | HENDERSON MICHAEL THOMAS | other | 3,000 |
Our APGE Coverage
We haven't published any research on APGE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APGE Report →